Show simple item record

dc.contributor.authorArcidiacono, Maria V.
dc.contributor.authorRimondi, Erika
dc.contributor.authorMaietti, Elisa
dc.contributor.authorMelloni, Elisabetta
dc.contributor.authorTisato, Veronica
dc.contributor.authorGallo, Stefania
dc.contributor.authorValdivielso Revilla, José Manuel
dc.contributor.authorFernández i Giráldez, Elvira
dc.contributor.authorBetriu i Bars, M. Àngels
dc.contributor.authorVoltan, Rebecca
dc.contributor.authorZauli, Giorgio
dc.contributor.authorVolpato, Stefano
dc.contributor.authorSecchiero, Paola
dc.description.abstractBackground: Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Methods: Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. Results: The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Conclusions: Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.
dc.description.sponsorshipThe NEFRONA study was funded by a research grant from Abbvie and the Spanish government RETIC (RD16/0009/0011) and FISPI16/01354. MVA is the recipient of the Italian Ministry of Health grant No. GR-2013-0 2358192. SG is the recipient of the "Associazione Italiana per la Ricerca sul Cancro, AIRC" fellowship, No. 18055. Moreover, the authors would like to thank Fondazione Dott. Carlo Fornasini (Poggio Renatico, Ferrara, Italy). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.publisherPublic Library of Science
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofPlos One, 2018, vol. 13, num. 9, p. e0203716
dc.rightscc-by (c) Arcidiacono, Maria V. et al., 2018
dc.subjectRonyons -- Malalties
dc.titleRelationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Arcidiacono, Maria V. et al., 2018
Except where otherwise noted, this item's license is described as cc-by (c) Arcidiacono, Maria V. et al., 2018